Search results for "ZOL"

showing 10 items of 4792 documents

Self- and observer assessment in anxiolytic drug trials: A comparison of their validity

1990

Self-rating scales are considered to be less useful for comparing different treatments in anxiety patients than observer-rating scales. However, the empirical evidence for this assumption is not adequate. A self-rating inventory of 35 items related to anxiety was perfectly parallel with an observer-rating inventory. Both instruments were used in the Cross National Collaborative Panic Study to compare the efficacy of imipramine, alprazolam and placebo in an 8-week drug trial in a sample of 1168 outpatients. The variance of the self-rating assessments was about two times higher. Both scales were equally sensitive to change; however, the measurement of change by means of the self-rating scale …

AdultPersonality TestsImipraminemedicine.medical_specialtyPsychometricsPsychometricsmedicine.drug_classPersonality AssessmentAnxiolyticDouble-Blind MethodRating scalemedicineHumansPharmacology (medical)PsychiatryBiological PsychiatryAlprazolamGeneral NeurosciencePanic disorderReproducibility of ResultsPanicGeneral MedicineMiddle Agedmedicine.diseaseAnxiety DisordersPanicPsychiatry and Mental healthNeuropsychology and Physiological PsychologyAlprazolamAnxietymedicine.symptomPersonality Assessment InventoryPsychologyClinical psychologymedicine.drugEuropean Archives of Psychiatry and Clinical Neuroscience
researchProduct

Impaired Cardiopulmonary Exercise Capacity in Patients With Hyperthyroidism

1996

Hyperthyroidism (H) has been implicated as a primary cause of decreased exercise tolerance. To our knowledge, analysis of respiratory gas exchange, an efficient noninvasive method in evaluating cardiopulmonary capacity, has not been performed in patients with H.Using cardiopulmonary exercise testing, 12 consecutive women with Graves' H were examined and controlled in euthyroidism (E). Eighteen women with E, in whom cardiac catheterization had ruled out heart disease, served as control subjects (C).The ventilatory anaerobic threshold was determined by means of the V-slope method. Ergometry was performed with patients in a semisupine position using a continuous ramp protocol of 20 W/min. Echo…

AdultPulmonary and Respiratory MedicineCardiac outputmedicine.medical_specialtySupine positionAnaerobic ThresholdHeart diseaseRestmedicine.medical_treatmentPhysical exerciseCritical Care and Intensive Care MedicineOxygen ConsumptionAntithyroid AgentsHeart RateInternal medicineHeart rateSupine PositionTidal VolumemedicineHumansProspective StudiesCardiac OutputLungAgedCardiac catheterizationExercise ToleranceMethimazolePulmonary Gas Exchangebusiness.industryHeartStroke VolumeStroke volumeMiddle Agedmedicine.diseaseGraves DiseaseSurgeryEchocardiographyExercise TestLinear ModelsCardiologyFemaleCardiology and Cardiovascular MedicinebusinessAnaerobic exerciseChest
researchProduct

Sudden upper airway obstruction in patients with hereditary angioedema.

2003

Hereditary angioedema (HAE) is clinically characterized by recurrent and self-limiting skin, intestinal, and life-threatening laryngeal edema. This study describes the age at which laryngeal edema first occurred, the time between onset and full development, and the effectiveness of therapy and prophylaxis in 123 HAE patients. 61 (49.7%) patients experienced a total of 596 laryngeal edema episodes. The ratio of laryngeal edema episodes to skin swellings and abdominal pain attacks was approximately 1:70:54 in patients who had laryngeal edema. The mean (SD) age at the first laryngeal edema was 26.2 (15.3) years. Nearly 80% of the laryngeal edemas occurred between age 11 and 45. The mean interv…

AdultRiskAbdominal painmedicine.medical_specialtyTime FactorsAdolescentComplement C1 Inactivator ProteinsLaryngeal EdemaC1-inhibitormedicineHumansYoung adultAge of OnsetAngioedemaChildDanazolbiologybusiness.industryAge FactorsHematologyAirway obstructionLaryngeal EdemaMiddle Agedmedicine.diseaseSurgeryAirway ObstructionAnesthesiaHereditary angioedemaAcute Diseasebiology.proteinmedicine.symptomAge of onsetbusinessmedicine.drugTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
researchProduct

Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, …

2012

The objective of the study was to compare the efficacy and safety of frovatriptan and almotriptan in women with menstrually related migraine (IHS Classification of Headache disorders) enrolled in a multicenter, randomized, double-blind, cross-over study. Patients received frovatriptan 2.5 mg or almotriptan 12.5 mg in a randomized sequence: after treating 3 episodes of migraine in no more than 3 months with the first treatment, the patient was switched to the other treatment. 67 of the 96 female patients of the intention-to-treat population of the main study had regular menstrual cycles and were thus included in this subgroup analysis. 77 migraine attacks classified as related to menses were…

AdultTime FactorsOriginalMigraine DisordersPopulationAlmotriptanClinical NeurologyCarbazolesSubgroup analysisSeverity of Illness IndexAdult; Carbazoles; Cross-Over Studies; Disability Evaluation; Double-Blind Method; Female; Humans; Italy; Menstruation Disturbances; Middle Aged; Migraine Disorders; Proportional Hazards Models; Serotonin Receptor Agonists; Severity of Illness Index; Time Factors; Treatment Outcome; TryptaminesDisability EvaluationDouble-Blind MethodAlmotriptanSeverity of illnessMedicineHumanseducationMigraine Menstrually related migraine Frovatriptan AlmotriptanMenstrually related migraineMenstruation DisturbancesMigraineMenstrually related migraineProportional Hazards Modelseducation.field_of_studyCross-Over Studiesbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseCrossover studyTryptaminesSerotonin Receptor Agonistsfrovatriptan; migraine; menstrually related migraine; almotriptanAnesthesiology and Pain MedicineTreatment OutcomeMigraineItalyAnesthesiaFemaleNeurology (clinical)businessFrovatriptanFrovatriptanmedicine.drug
researchProduct

Papular pruritic eruption with human immunodeficiency virus infection.

1991

Adultbusiness.industryPruritusHuman immunodeficiency virus (HIV)DermatitisHIV InfectionsDermatologymedicine.disease_causeVirologyMetronidazolemedicineHumansFemalebusinessZidovudineInternational journal of dermatology
researchProduct

Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy.

2009

Background Hereditary angioedema caused by mutations in the factor XII gene is a recently described disease entity that occurs mainly in women. It differs from hereditary angioedema caused by C1 inhibitor deficiency. Objective To assess the clinical symptoms, factors triggering acute attacks, and treatments of this disease. Methods Thirty-five female patients with hereditary angioedema and the factor XII mutations p.Thr309Lys and p.Thr309Arg who came from 13 unrelated families were studied. The observation period was 8.4 years on average (range, 2-26 years). Results Patients had on average 12.7 ± 7.9 angioedema attacks per year. Recurrent facial swellings occurred in all patients; skin swel…

Adultmedicine.medical_specialtyAbdominal painAdolescentmedicine.medical_treatmentImmunologyMutation MissenseSeverity of Illness IndexC1-inhibitorYoung AdultRisk FactorsSurveys and QuestionnairesImmunology and AllergyMedicineHumansHereditary Angioedema Type IIIAge of OnsetChildProgesteroneDanazolPregnancyAngioedemabiologybusiness.industryDanazolAngioedemas HereditaryHormone replacement therapy (menopause)Middle Agedmedicine.diseaseDermatologySurgeryPedigreeTranexamic AcidHereditary angioedemaFactor XIIbiology.proteinFemalemedicine.symptombusinessmedicine.drugThe Journal of allergy and clinical immunology
researchProduct

Effects of leflunomide (HWA 486) on expression of lymphocyte activation markers

1993

Leflunomide (HWA 486), an isoxazol derivative, has been shown to be very effective in combating autoimmune diseases and transplantation rejection in a great number of animal models. The main metabolite of leflunomide, A77 1726, is a potent antiproliferative compound. To further elucidate this effect, lymphocytes of healthy human donors were cultured for 24, 48 or 72 h in the presence of PHA or immobilized anti-CD3 antibody. A77 1726 was added at concentrations between 10 and 100 microM. Flow cytometric evaluation of early activation or proliferation markers (IL-2 and transferrin receptors, respectively) showed that their expression was inhibited in a dose-dependent manner by A77 1726. Toget…

Adultmedicine.medical_specialtyAllergyToluidinesMetaboliteImmunologyHydroxybutyratesTransferrin receptorBiologyPharmacologyLymphocyte ActivationToxicologychemistry.chemical_compoundImmune systemInternal medicineNitrilesReceptors TransferrinmedicineHumansPharmacology (medical)PhytohemagglutininsLeflunomidePharmacologyAniline CompoundsAnti-Inflammatory Agents Non-SteroidalReceptors Interleukin-2Isoxazolesmedicine.diseaseRheumatologyTransplantationchemistryCrotonatesImmunologybiology.proteinAntibodyBiomarkersLeflunomidemedicine.drugAgents and Actions
researchProduct

Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients

2016

Background Invasive fungal infections are important causes of morbidity and mortality among critically ill patients. Early institution of antifungal therapy is pivotal for mortality reduction. Starting a targeted antifungal therapy after culture positivity and fungi identification requires a long time. Therefore, alternative strategies (globally defined as 'untargeted antifungal treatments') for antifungal therapy institution in patients without proven microbiological evidence of fungal infections have been discussed by international guidelines. This review was originally published in 2006 and updated in 2016. This updated review provides additional evidence for the clinician dealing with s…

Adultmedicine.medical_specialtyAntifungal drugMycoseintensive care medicinelaw.invention03 medical and health sciencesImmunocompromised Hostcritically ill patient0302 clinical medicineRandomized controlled triallawInternal medicineAmphotericin BmedicineHumansAntifungal AgentPharmacology (medical)030212 general & internal medicineMED/41 - ANESTESIOLOGIAIntensive care medicineFluconazoleFluconazole [therapeutic use]Randomized Controlled Trials as Topicbusiness.industryfungal infectionMicafungin030208 emergency & critical care medicinePublication biasMycoses [mortalityClinical trialCritical Illness [mortality]; Amphotericin B [therapeutic use]; Antifungal Agents [therapeutic use]; Fluconazole [therapeutic use]; Immunocompromised Host; Mycoses [mortality; prevention & control]; Randomized Controlled Trials as Topic; Adult; HumansAntifungal Agents [therapeutic use]prevention & control]Relative riskMeta-analysisAmphotericin B [therapeutic use]AnidulafunginCritical IllneCritical Illness [mortality]businessmedicine.drugHuman
researchProduct

Acoustic Airway Profiles in Unilateral Cleft Palate Patients

1999

Objective: This study investigates the nasal airway in unilateral cleft palate patients by means of a noninvasive, objective diagnostic method that provides topographic information about the airway profile. Design: A consecutive sample of patients was measured. Setting: Cleft palate rehabilitation center of the University of Mainz, Germany. Patients: Forty-nine subjects were investigated: 34 full-grown patients with complete unilateral cleft lip and palate and 15 controls with subjective normal nasal patency. Intervention: A transnasal series of three acoustic measurements of nasal volume was performed per nostril; measurements were taken both before and after decongestion with 0.3 mg xylom…

Adultmedicine.medical_specialtyDiagnostic methodsAdolescentNostrilBiophysicsNoseStatistics NonparametricUnilateral cleft palateNasal airwayXylometazolineCONSECUTIVE SAMPLE03 medical and health sciences0302 clinical medicineAcoustic Impedance TestsmedicineHumans030223 otorhinolaryngologybusiness.industryImidazolesAcoustics030206 dentistrySurgeryCleft PalateNasal Decongestantsmedicine.anatomical_structureOtorhinolaryngologyNasal CavityNasal ObstructionOral SurgeryAirwaybusinessmedicine.drugThe Cleft Palate-Craniofacial Journal
researchProduct

Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomi…

2012

Background and objective: Thrombopoietin receptor (TPOr) agonists (romiplostim and eltrombopag) are a new approach for the treatment of thrombocytopenia-associated conditions. They promote megakaryocyte differentiation, proliferation and platelet production. In the European Union, both are orphan drugs with an indication restricted to splenectomized immune thrombocytopenic purpura patients who are refractory to other treatments. Due to increasing platelet counts, these drugs may represent a risk for thromboembolic complications. We analyzed whether TPOr agonists affect thromboembolisms occurrence in adult thrombocytopenic patients. Materials and methods: We conducted a systematic review and…

Adultmedicine.medical_specialtyMegakaryocyte differentiationRecombinant Fusion ProteinsEltrombopagReceptors FcBenzoateslaw.inventionchemistry.chemical_compoundRandomized controlled triallawRisk FactorsInternal medicineHematologic AgentsThromboembolismmedicinemedia_common.cataloged_instanceHumansEuropean unionmedia_commonRandomized Controlled Trials as TopicRomiplostimbusiness.industryGeneral MedicineNumber needed to harmThrombocytopeniaSurgeryHydrazineschemistryThrombopoietinMeta-analysisRelative riskPyrazolesbusinessReceptors Thrombopoietinmedicine.drugMedicina clinica
researchProduct